000270674 001__ 270674
000270674 005__ 20240808164333.0
000270674 0247_ $$2doi$$a10.3233/JAD-231335
000270674 0247_ $$2pmid$$apmid:38848176
000270674 0247_ $$2ISSN$$a1387-2877
000270674 0247_ $$2ISSN$$a1875-8908
000270674 0247_ $$2altmetric$$aaltmetric:164555868
000270674 037__ $$aDZNE-2024-00846
000270674 041__ $$aEnglish
000270674 082__ $$a610
000270674 1001_ $$aSannemann, Lena$$b0
000270674 245__ $$aSymptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.
000270674 260__ $$aAmsterdam$$bIOS Press$$c2024
000270674 3367_ $$2DRIVER$$aarticle
000270674 3367_ $$2DataCite$$aOutput Types/Journal article
000270674 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721814563_7926
000270674 3367_ $$2BibTeX$$aARTICLE
000270674 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000270674 3367_ $$00$$2EndNote$$aJournal Article
000270674 520__ $$aThe NIA-AA Research Framework on Alzheimer's disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective cognitive decline (SCD) and mild neurobehavioral symptoms (NPS).To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals.We included baseline data of N = 338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on Aβ42/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed.We identified three distinct participant clusters based on presented symptoms. The highest rate of A+ participants (47.6%) was found in a cluster characterized by both OBJ and SCD. A cluster of participants that presented with SCD and NPS (A+:26.6%) and a cluster of participants with overall few symptoms (A+:19.7%) showed amyloid positivity in a range that was not higher than the expected A+ rate for the age group. Across the full sample, participants with a combination of SCD and OBJ in the memory domain showed a lower Aβ42/ptau181 ratio compared to those with neither SCD nor OBJ.The cluster characterized by participants with OBJ and concomitant SCD was enriched for amyloid pathology.
000270674 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000270674 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000270674 650_2 $$2MeSH$$aHumans
000270674 650_2 $$2MeSH$$aMale
000270674 650_2 $$2MeSH$$aFemale
000270674 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000270674 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000270674 650_2 $$2MeSH$$aAged
000270674 650_2 $$2MeSH$$aCognitive Dysfunction: cerebrospinal fluid
000270674 650_2 $$2MeSH$$aCognitive Dysfunction: psychology
000270674 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000270674 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000270674 650_2 $$2MeSH$$aPeptide Fragments: cerebrospinal fluid
000270674 650_2 $$2MeSH$$aNeuropsychological Tests
000270674 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000270674 650_2 $$2MeSH$$aAlzheimer Disease: psychology
000270674 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000270674 650_2 $$2MeSH$$aMiddle Aged
000270674 650_2 $$2MeSH$$aCohort Studies
000270674 650_2 $$2MeSH$$aAged, 80 and over
000270674 650_2 $$2MeSH$$aCluster Analysis
000270674 650_7 $$2Other$$aAlzheimer’s disease
000270674 650_7 $$2Other$$aAlzheimer’s disease
000270674 650_7 $$2Other$$aAlzheimer’s disease continuum
000270674 650_7 $$2Other$$aNIA-AA stage 2
000270674 650_7 $$2Other$$aamyloid
000270674 650_7 $$2Other$$acerebrospinal fluid biomarkers
000270674 650_7 $$2Other$$aneuropsychiatric symptoms
000270674 650_7 $$2Other$$apreclinical Alzheimer’s disease
000270674 650_7 $$2Other$$asubjective cognitive decline
000270674 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000270674 650_7 $$2NLM Chemicals$$aBiomarkers
000270674 650_7 $$2NLM Chemicals$$aPeptide Fragments
000270674 650_7 $$2NLM Chemicals$$aamyloid beta-protein (1-42)
000270674 650_7 $$2Other$$aAlzheimer’s disease continuum
000270674 650_7 $$2Other$$apreclinical Alzheimer’s disease
000270674 693__ $$0EXP:(DE-2719)DELCODE-20140101$$5EXP:(DE-2719)DELCODE-20140101$$eLongitudinal Cognitive Impairment and Dementia Study$$x0
000270674 7001_ $$aBartels, Claudia$$b1
000270674 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b2$$udzne
000270674 7001_ $$0P:(DE-2719)2811351$$aBuerger, Katharina$$b3$$udzne
000270674 7001_ $$0P:(DE-2719)2811326$$aFliessbach, Klaus$$b4$$udzne
000270674 7001_ $$0P:(DE-2719)2812392$$aFreiesleben, Silka Dawn$$b5$$udzne
000270674 7001_ $$0P:(DE-2719)2810481$$aFrommann, Ingo$$b6$$udzne
000270674 7001_ $$0P:(DE-2719)2811614$$aGlanz, Wenzel$$b7$$udzne
000270674 7001_ $$0P:(DE-2719)2000008$$aHeneka, Michael$$b8$$udzne
000270674 7001_ $$0P:(DE-2719)9002557$$aJanowitz, Daniel$$b9$$udzne
000270674 7001_ $$0P:(DE-2719)2810394$$aKilimann, Ingo$$b10$$udzne
000270674 7001_ $$0P:(DE-2719)2812139$$aKleineidam, Luca$$b11$$udzne
000270674 7001_ $$0P:(DE-HGF)0$$aLammerding, Dominik$$b12
000270674 7001_ $$0P:(DE-2719)2000055$$aLaske, Christoph$$b13$$udzne
000270674 7001_ $$0P:(DE-2719)9001516$$aMunk, Matthias H J$$b14$$udzne
000270674 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b15$$udzne
000270674 7001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b16$$udzne
000270674 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b17$$udzne
000270674 7001_ $$0P:(DE-2719)9001808$$aRauchmann, Boris Stephan$$b18$$udzne
000270674 7001_ $$0P:(DE-HGF)0$$aRostamzadeh, Ayda$$b19
000270674 7001_ $$0P:(DE-2719)2812341$$aRoy-Kluth, Nina$$b20$$udzne
000270674 7001_ $$0P:(DE-2719)9001495$$aSchild, Ann-Katrin$$b21
000270674 7001_ $$0P:(DE-2719)2812035$$aSchneider, Anja$$b22$$udzne
000270674 7001_ $$0P:(DE-2719)9002878$$aSchneider, Luisa-Sophie$$b23$$udzne
000270674 7001_ $$0P:(DE-2719)2811324$$aSpottke, Annika$$b24$$udzne
000270674 7001_ $$0P:(DE-2719)2812446$$aSpruth, Eike Jakob$$b25
000270674 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b26$$udzne
000270674 7001_ $$0P:(DE-2719)2000057$$aWagner, Michael$$b27$$udzne
000270674 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b28$$udzne
000270674 7001_ $$0P:(DE-2719)2810544$$aWolfsgruber, Steffen$$b29$$udzne
000270674 7001_ $$0P:(DE-2719)2000005$$aDuezel, Emrah$$b30$$udzne
000270674 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b31$$eLast author$$udzne
000270674 7001_ $$0P:(DE-HGF)0$$aGroup, DELCODE Study$$b32$$eCollaboration Author
000270674 773__ $$0PERI:(DE-600)2070772-1$$a10.3233/JAD-231335$$gVol. 100, no. 1, p. 193 - 205$$n1$$p193 - 205$$tJournal of Alzheimer's disease$$v100$$x1387-2877$$y2024
000270674 8564_ $$uhttps://pub.dzne.de/record/270674/files/DZNE-2024-00846_Restricted.pdf
000270674 8564_ $$uhttps://pub.dzne.de/record/270674/files/DZNE-2024-00846_Restricted.pdf?subformat=pdfa$$xpdfa
000270674 909CO $$ooai:pub.dzne.de:270674$$pVDB
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810593$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811351$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811326$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812392$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810481$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811614$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000270674 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2000008$$aExternal Institute$$b8$$kExtern
000270674 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002557$$aExternal Institute$$b9$$kExtern
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810394$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812139$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000055$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001516$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811024$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b17$$kDZNE
000270674 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001808$$aExternal Institute$$b18$$kExtern
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812341$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b20$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812035$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b22$$kDZNE
000270674 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002878$$aExternal Institute$$b23$$kExtern
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811324$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812446$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b25$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b26$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000057$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b27$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b28$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810544$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b29$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b30$$kDZNE
000270674 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b31$$kDZNE
000270674 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000270674 9141_ $$y2024
000270674 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ALZHEIMERS DIS : 2022$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000270674 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000270674 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x0
000270674 9201_ $$0I:(DE-2719)1011303$$kAG Heneka$$lNeuroinflammation, Biomarker$$x1
000270674 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x2
000270674 9201_ $$0I:(DE-2719)1011101$$kPatient Studies Bonn ; Patient Studies (Bonn)$$lPatient Studies (Bonn)$$x3
000270674 9201_ $$0I:(DE-2719)5000000$$kAG Peters$$lBiomarker-Assisted Early Detection of Dementias$$x4
000270674 9201_ $$0I:(DE-2719)1011201$$kAG Wagner$$lNeuropsychology$$x5
000270674 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x6
000270674 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x7
000270674 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x8
000270674 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x9
000270674 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x10
000270674 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Research Platform (CRP)$$x11
000270674 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x12
000270674 980__ $$ajournal
000270674 980__ $$aVDB
000270674 980__ $$aI:(DE-2719)1011102
000270674 980__ $$aI:(DE-2719)1011303
000270674 980__ $$aI:(DE-2719)1111015
000270674 980__ $$aI:(DE-2719)1011101
000270674 980__ $$aI:(DE-2719)5000000
000270674 980__ $$aI:(DE-2719)1011201
000270674 980__ $$aI:(DE-2719)5000006
000270674 980__ $$aI:(DE-2719)1510100
000270674 980__ $$aI:(DE-2719)1210000
000270674 980__ $$aI:(DE-2719)5000022
000270674 980__ $$aI:(DE-2719)5000007
000270674 980__ $$aI:(DE-2719)1011103
000270674 980__ $$aI:(DE-2719)1410006
000270674 980__ $$aUNRESTRICTED